EUS-RFA PANCARDINAL-1 Trial
Recruiting · NCT04990609 · Interventional (participants receive a specific treatment) · Lead sponsor: The University of Texas Health Science Center, Houston
View the official record on ClinicalTrials.gov →Interventions studied
Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)Neoadjuvant Chemotherapy (NAC)
What this trial is about
The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) and neoadjuvant chemotherapy (NAC) will be performed before tumor resection surgery, with the goal of shrinking a tumor or stopping the spread of cancer so that surgery might be less invasive and more effective.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Diagnosed and histologically-confirmed PDAC by biopsy
- Permanent street address
- Consent to study participation
- Axial CT scan consistent with PDAC
- No prior chemotherapy or less than 2 months of pre-operative chemotherapy for PDAC
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Exclusion criteria
- Male or female patients \< 18 years of age
- No permanent street address or telephone number
- Pregnant patients
- Inmates or prisoners
- Unable to provide informed consent
Where it is running
1 location listed across 1 US state.
- Memorial Hermann Hospital - Houston, Texas, United States